Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary Axillary Hyperhidrosis
- The US FDA has cleared Brella, 3-Minute SweatControl Patch for adult patients with PAH. The needle-free, aluminum-free Brella SweatControl patch delivers results that can last for 3-4mos.
- The clearance was based on the (SAHARA) trial in 110 adult patients. The trial met its 1EPs & 2EPs i.e., new non-invasive treatment significantly reduces excessive underarm sweating and improves QoL incl. reducing the negative impact of excessive sweating on daily activities & was well tolerated with no serious or sev. AEs. The results were presented at AAD 2023 & will be submitted to a peer-reviewed dermatology publication
- Brella will be available in US markets in late summer of 2023 via Candesant Brella early experience program & the product will then be made available across the country
Ref: PR Newswire | Image: Candesant
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.